Ann Pharmacol Pharm | Volume 5, Issue 5 | Short Communication | Open Access
Norio Ogata* and Takanori Miura
Department of R&D, Taiko Pharmaceutical Co. Ltd, Japan
*Correspondance to: Norio Ogata
Fulltext PDFAim: The new Coronavirus (SARS-CoV-2) responsible for COVID-19 disease is still a significant threat and no effective and convenient method for decontamination of this virus exists as yet. We aimed to evaluate the effect of a novel method for the decontamination of the virus using aqueous Chlorine Dioxide (ClO2) solution. SARS-CoV-2 virus uses its “spike protein” to adhere to human cells containing Angiotensin-Converting Enzyme 2 (ACE2), which acts as a receptor protein.
Materials and Methods: In an in vitro experiment, the spike protein was treated with 0.5 mmol/L chlorine dioxide solution at room temperature for 5 min, and the binding of the spike protein to ACE2 was quantitated by a chemiluminescence reaction.
Findings: The binding of the spike protein to ACE2 decreased to 1.9% of the control (no chlorine dioxide) (n=4, p<0.001).
Conclusion: The result strongly indicates the usefulness of chlorine dioxide solution as a decontamination method of SARS-CoV-2 virus.
Chlorine dioxide; SARS-CoV-2 virus; COVID-19; Angiotensin-converting enzyme 2
Ogata N, Miura T. Inhibition of the Binding of Spike Protein of SARSCoV- 2 Coronavirus to Human Angiotensin-Converting Enzyme 2 by Chlorine Dioxide. Ann Pharmacol Pharm. 2020;5(5):1195..